Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe ...

Discover Trametinib as a promising treatment for severe hypertrophic cardiomyopathy in children with RASopathies.

In contrast, the signal proceeds normally or with greater strength (because of compensatory hyperinsulinemia of various degrees) along the Shc-Ras-MAP kinase pathway, eliciting greater responses ...

Additionally, the Phase 1 clinical trial evaluating QTX3034, an oral G12D-preferring multi-KRAS inhibitor, as a monotherapy and in combination with cetuximab, continues to enroll patients, and data is ...

found in up to 85% of cancers driven by RAS alterations. Developed in-house, BAY3498264 addresses the unmet medical need of improving efficacy of treatment targeting the mitogen-activated protein ...

initiating signal transduction via pathways that include the Ras/mitogen-activated protein kinase pathway, the phosphatidylinositol 3' kinase (PI3K)/Akt pathway, and then Janus kinases/signal ...

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with ...

OS is an important factor that leads to DNA damage and stimulates carcinogenesis through dysregulation of signaling pathways that are important for tumor survival and metastasis. Studies have ...

Historically, scientists in the division were the first to make the ground-breaking discovery of the mechanism by which the RAS gene – one of the ... through activation of the ERK-MAP kinase cell ...